Mephedrone and Nicotine: Oxidative Stress and Behavioral Interactions in Animal Models

Neurochemical Research

Volumn 40, Issue 5, 2015, Pages 1083-1093

  Budzynska, Barbara ^a   Boguszewska Czubara, Anna ^a   Kruk Slomka, Marta ^a   Kurzepa, Jacek ^a   Biala, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Anxiety; Locomotor sensitization; Memory; Mephedrone; Nicotine; Oxidative stress

Indexed keywords

4' METHYLMETHCATHINONE; DRUG COMBINATION; METHAMPHETAMINE; NICOTINE; STREET DRUG;

ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; ANXIETY; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; MALE; MAZE TEST; MEMORY; MOTOR ACTIVITY; MOUSE; OXIDATIVE STRESS; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; ANXIETY; DRUG COMBINATIONS; MALE; MAZE LEARNING; MEMORY; METHAMPHETAMINE; MICE; MODELS, ANIMAL; MOTOR ACTIVITY; NICOTINE; OXIDATIVE STRESS; STREET DRUGS;

EID: 84937758192     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-015-1566-5     Document Type: Article

References (70)

1. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, Thomas SH (2011) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 28:686–689
2. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farre M, Torrens M, Demetrovics Z, Ghodse AH (2011) Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical pharmacological and clinical issues. Psychopharmacology 214:593–602
3. Winstock AR, Marsden J, Mitcheson L (2010) What should be done about mephedrone? BMJ 340:c1605
4. Kehr JF, Ichinose S, Yoshitake M, Goiny T, Sievertsson F, Nyberg T, Yoshitake T (2011) Mephedrone compared to MDMA (ecstasy) and amphetamine rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949–1958
5. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339(2):530–536
6. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22(3):231–236
7. Motbey CP, Karanges E, Li KM, Wilkinson S, Winstock AR, Ramsay J, Hicks C, Kendig MD, Wyatt N, Callaghan PD, McGregor IS (2012) Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 7(9):e45473. doi:10.1371/journal.pone.0045473
8. Angoa-Pérez M, Kane MJ, Briggs DI, Francescutti DM, Sykes CE, Shah MM, Thomas DM, Kuhn DM (2013) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem 125(1):102–110. doi:10.1111/jnc.12114
9. Angoa-Pérez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, Mohammed AM, Thomas DM, Kuhn DM (2012) Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 120(6):1097–1107. doi:10.1111/j.1471-4159.2011.07632.x
10. Angoa-Pérez M, Kane MJ, Herrera-Mundo N, Francescutti DM, Kuhn DM (2014) Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci 97(1):31–36. doi:10.1016/j.lfs.2013.07.015
11. Gonçalves J, Baptista S, Silva AP (2014) Psychostimulants and brain dysfunction: a review of the relevant neurotoxic effects. Neuropharmacology 87:135–149. doi:10.1016/j.neuropharm.2014.01.006
12. Wonnacott S (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92–98
13. Herman AI, Sofuoglu M (2010) Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep 12:433–440
14. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53:633–640
15. Levin ED, Petro A, Rezvani AH, Pollard N, Christopher NC, Strauss M, Avery J, Nicholson J, Rose JE (2009) Nicotinic α7- or β2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res 196:207–213
16. Marubio LM, Arroyo-Jimenez MDM, Cordero-Erausquin M, Léna C, Le Novère N, de Kerchove d’Exaerde A, Huchet M, Damaj MI, Changeux JP (1999) Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398:805–810
17. File SE, Cheeta S, Kenny PJ (2000) Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 393:231–236
18. Hayase T (2011) Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. BMC Pharmacol 11:6
19. Biala G, Polak P, Michalak A, Kruk-Slomka M, Budzynska B (2014) Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice. Pharmacol Rep 66(2):212–222
20. Budzynska B, Polak P, Biala G (2012) Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm. Behav Brain Res 228(1):144–150
21. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446
22. Kruk-Slomka M, Budzynska B, Biala G (2012) Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice. Pharmacol Rep 64(5):1066–1080
23. Malin DH (2001) Nicotine dependence studies with a laboratory model. Pharmacol Biochem Behav 70:551–559
24. Yildiz D (2004) Nicotine its metabolism and an overview of its biological effects. Toxicon 43:619–632
25. Biala G, Staniak N (2010) Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacol Biochem Behav 96(2):141–147
26. López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone mephedrone and methylone. Br J Pharmacol 167(2):407–420
27. Biala G, Budzynska B (2006) Effects of acute and chronic nicotine on elevated plus maze in mice: involvement of calcium channels. Life Sci 79(1):81–88
28. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, Biala G, Glowniak K (2013) Effects of imperatorin on nicotine-induced anxiety- and memory-related responses and oxidative stress in mice. Physiol Behav 122:46–55
29. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92(2):180–185
30. Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, Dehpour AR (2011) Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 650:240–248
31. Javadi-Paydar M, Zakeri M, Norouzi A, Rastegar H, Mirazi N, Dehpour A (2012) Involvement of nitric oxide in granisetron improving effect on scopolamine-induced memory impairment in mice. Brain Res Rev 1429:61–71
32. Ledwozyw A, Michalak J, Stepien A, Kadziołka A (1986) The relationship between plasma triglycerides cholesterol total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 155(3):275–283
33. Chimakurthy J, Talasila M (2010) Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 3:239–244
34. Lenz J, Brown J, Flagg S, Oh R, Batts K, Ditzler T, Johnson J (2013) Cristalius: a case in designer drugs. Mil Med 178(7):e893–e895
35. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (ecstasy) use cognition and mood. Psychopharmacology 173:434–439
36. Moon M, Do KS, Park J, Kim D (2007) Memory impairment in methamphetamine dependent patients. Int J Neurosci 117:1–9
37. Wood DM, Dargan PI (2012) Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 34(4):363–367
38. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanperä I, Korpi ER (2013) Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone. Pharmacol Biochem Behav 103:501–509
39. Ciccarone D (2011) Stimulant abuse: pharmacology cocaine methamphetamine treatment attempts at pharmacotherapy. Prim Care 38:41–58
40. McKetin R, Mattick RP (1997) Attention and memory in illicit amphetamine users. Drug Alcohol Depend 48(3):235–242
41. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS (2012) Mephedrone (4-methylmethcathinone ‘meow’): acute behavioral effects and distribution of Fos expression in adolescent rats. Addict Biol 17(2):409–422
42. Nyberg F (2012) Cognitive impairments in drug addicts. In: González-Quevedo A (ed) Brain damage—bridging between basic research and clinics. InTech. doi:10.5772/37661
43. Strupp BJ, Bunsey M, Levitsky D, Kesler M (1991) Time-dependent effects of post-trial amphetamine treatment in rats: evidence for enhanced storage of representational memory. Behav Neural Biol 56(1):62–76
44. Kenney JW, Adoff MD, Wilkinson DS, Gould TJ (2011) The effects of acute chronic and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology 217(3):353–365. doi:10.1007/s00213-011-2283-7
45. Kenney JW, Gould TJ (2008) Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 38:101–121
46. Kenney JW, Gould TJ (2008) Nicotine enhances context learning but not context-shock associative learning. Behav Neurosci 122:1158–1165
47. Doty BA, Doty LA (1966) Facilitative effects of amphetamine on avoidance conditioning in relation to age and problem difficulty. Psychopharmacology 9(3):234–241
48. Krivanek JA, McGaugh JL (1969) Facilitating effects of pre- and post-trial amphetamine administration on discrimination learning in mice. Agents Actions 1(2):36–42
49. Sesack SR, Pickel VM (1990) In the rat medial nucleus accumbens hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 527(2):266–279
50. Tokunaga M, Seneca N, Shin RM, Maeda J, Obayashi S, Okauchi T, Nagai Y, Zhang MR, Nakao R, Ito H, Innis RB, Halldin C, Suzuki K, Higuchi M, Suhara T (2009) Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci 29(6):1887–1896
51. Levin ED, Rezvani AH (2007) Nicotinic interactions with antipsychotic drugs models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 74:1182–1191
52. Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacology 108:417–443
53. Picciotto MR, Caldarone BJ, King SL, Zachariou V (2000) Nicotinic receptors in the brain Links between molecular biology and behavior. Neuropsychopharmacology 22:451–465
54. Sparks JA, Pauly JR (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57BL/6 mice. Psychopharmacology 141:145–153
55. Ma Q (2014) Advances in mechanisms of anti-oxidation. Discov Med 17(93):121–130
56. Dafny N, Yang PB (2006) The role of age genotype sex and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 68:393–405
57. Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16:223–244
58. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18(3):247–291
59. Vanderschuren LJ, Schmidt ED, De Vries TJ, Van Moorsel CA, Tilders FJ, Schoffelmeer AN (1999) A single exposure to amphetamine is sufficient to induce long-term behavioral neuroendocrine and neurochemical sensitization in rats. J Neurosci 19:9579–9586
60. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396(2):157–198
61. Hope BT, Simmons DE, Mitchell TB, Kreuter JD, Mattson BJ (2006) Cocaine-induced locomotor activity and Fos expression in nucleus accumbens are sensitized for 6 months after repeated cocaine administration outside the home cage. Eur J Neurosci 24(3):867–875
62. Vanderschuren LJ, Kalivas PW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151(2–3):99–120
63. DiFranza JR, Wellman RJ (2007) Sensitization to nicotine: how the animal literature might inform future human research. Nicotine Tob Res 9:9–20
64. Akimoto K, Hammurabi T, Kazahaya Y, Akiyama K, Otsuki S (1990) Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine-an in vivo dialysis study in freely moving rats. Brain Res 507:344–346
65. Cunningham ST, Kelley AE (1992) Evidence for opiate-dopamine cross-sensitization in nucleus accumbens: studies of conditioned reward. Brain Res Bull 29:675–680
66. Aizenstein ML, Segal DS, Kuczenski R (1990) Repeated amphetamine and fencamfamine: sensitization and reciprocal cross-sensitization. Neuropsychopharmacology 3:283–290
67. Clarke PB, Kumar R (1983) Characterization of the locomotor stimulant action of nicotine in tolerant rats. Br J Pharmacol 80:587–594
68. Clarke PB, Kumar R (1983) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78:329–337
69. Baker LK, Mao D, Chi H, Govind AP, Vallejo YF, Iacoviello M, Herrera S, Cortright JJ, Green WN, McGehee DS, Vezina P (2013) Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitizes locomotor responding to the drug. Eur J Neurosci 37(6):1004–1011
70. Lisek R, Xu W, Yuvasheva E, Chiu Y, Reitz AB, Liu-Chen L, Rawls SM (2012) Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend 126:257–262